Economic evaluation of a routine rotavirus vaccination programme in Indonesia

Wilopo, Siswanto Agus; Kilgore, Paul E.; Kosen, Soewarta; Soenarto, Yati; Aminah, Sri; Cahyono, Anton; Ulfa, Maria; Tholib, Abu

doi:10.1016/j.vaccine.2009.09.040

Cited by 45 publications

(42 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assuming a vaccine coverage of 80% and vaccine efficacies of 93% (first dose) and 95% (second dose), vaccination of 4 200 000 infants 9 and 6614 discounted quality-adjusted-life years (QALYs) for the two-dose and one-dose vaccine schedules, respectively. Furthermore, it also would save US$ 3 795 148 and US$ 2 892 920 from the societal perspective for both schedules, respectively, in the context of hepatitis A treatment ( Table 1A).…”

Section: Baseline Analysesmentioning

confidence: 99%

“…In this study, we used the Indonesia 2012 birth cohort of 4 200 000 infants 9 in an age-structured cohort model based on a decision tree. The model involves a 70-y time horizon (the average life expectancy in Indonesia) 28 with 1-mo cycles for children less than 2-y-old and annually thereafter.…”

Section: Modelmentioning

confidence: 99%

“…30 These healthcare costs were compiled from the information on disease rates, treatment-seeking rates, treatment practices, and unit costs, which were applied country-wide based on the available costing studies conducted in Indonesia. 30 For societal costs, we additionally took direct nonmedical costs (e.g., transportation) and indirect costs (e.g., productivity loss) 9 into account. Vaccine price and administration cost per dose were applied at US$ 3.21 37 and US$ 0.36, 9 respectively, based on previous studies in Indonesia.…”

Section: Qaly (Quality-adjusted-life-year) Lossesmentioning

confidence: 99%

See 2 more Smart Citations

Cost-effectiveness of hepatitis A vaccination in Indonesia

Suwantika

Beutels

Postma

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Baseline Analysesmentioning

confidence: 99%

Section: Modelmentioning

confidence: 99%

Section: Qaly (Quality-adjusted-life-year) Lossesmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of hepatitis A vaccination in Indonesia

Suwantika

Beutels

Postma

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…The estimates for expenses on each of these categories and data on percentage of children hospitalised for diarrhoea are from Wilopo et al (2009). The percentage of hospitalisations from diarrhoea in Indonesia until 5 years of age is 9.9 per cent, calculated as the ratio of total diarrhoea hospitalisations to the total diarrhoea cases, which we break up by age using available literature such as Quintanar-Solares et al (2011).…”

Section: Journal Of Development Effectiveness 455mentioning

confidence: 99%

“…For the cost of physician visits, Wilopo et al (2009) compute direct costs of medication and diagnosis, registration cost and cost of transport. We adjusted Wilopo et al's (2009) The cost of home treatment is the product of the probability of home treatment by age group times the number of episodes per child in this age group times the cost of home treatment.…”

Section: Journal Of Development Effectiveness 455mentioning

confidence: 99%

Positive returns: cost-benefit analysis of a stunting intervention in Indonesia

Qureshy

Alderman

Rokx

et al. 2013

Journal of Development Effectiveness

View full text Add to dashboard Cite

Would investing to reduce stunting reap economic benefits that outweigh costs? We investigate this question by conducting a cost-benefit analysis for a large-scale integrated nutrition programme to reduce stunting in Indonesia, using actual rather than stylised data on costs. The gains are assumed to accrue from productivity enhancement from reduced malnutrition, productive earnings from deaths averted and household savings from diarrhoea costs avoided. The programme extends to six provinces over 5 years covering seven cohorts. Using a discount rate of 5 per cent, the benefit-cost ratio is 2.08. The study finds positive net benefits through the productivity impact of lower malnutrition even with sensitivity analysis that excludes the benefits of mortality reduction.

show abstract

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in the Prevention of Rotavirus Gastroenteritis in Developing Countries

Plosker¹

2012

Pediatr Drugs

View full text Add to dashboard Cite

This article provides an overview of the clinical profile of rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis (RVGE) in developing countries, followed by a review of pharmacoeconomic analyses with the vaccine in low- and middle-income countries. RVGE is associated with significant morbidity and mortality among children <5 years of age in developing countries. The protective efficacy of a two-dose oral series of rotavirus vaccine RIX4414 has been demonstrated in several well designed clinical trials conducted in developing countries, and the 'real-world' effectiveness of the vaccine has also been shown in naturalistic and case-control trials after the introduction of universal vaccination programs with RIX4414 in Latin American countries. The WHO recommends universal rotavirus vaccination programs for all countries. Numerous modelled cost-effectiveness analyses have been conducted with rotavirus vaccine RIX4414 across a wide range of low- and middle-income countries. Although data sources and assumptions varied across studies, results of the analyses consistently showed that the introduction of the vaccine as part of a national vaccination program would be very cost effective compared with no rotavirus vaccination program, according to widely used cost-effectiveness thresholds for developing countries. Vaccine price was not known at the time the analyses were conducted and had to be estimated. In sensitivity analyses, rotavirus vaccine RIX4414 generally remained cost effective at the highest of a range of possible vaccine prices considered. Despite these favorable results, decisions regarding the implementation of universal vaccination programs with RIX4414 may also be contingent on budgetary and other factors, underscoring the importance of subsidized vaccination programs for poor countries through the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization).

show abstract

Economic evaluation of a routine rotavirus vaccination programme in Indonesia

Cited by 45 publications

References 22 publications

Cost-effectiveness of hepatitis A vaccination in Indonesia

Cost-effectiveness of hepatitis A vaccination in Indonesia

Positive returns: cost-benefit analysis of a stunting intervention in Indonesia

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in the Prevention of Rotavirus Gastroenteritis in Developing Countries

Contact Info

Product

Resources

About